NASDAQ:ACXP - US00510M1045 - Common Stock
The current stock price of ACXP is 4.145 USD. In the past month the price decreased by -18.57%. In the past year, price decreased by -89.53%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 20.01 | 374.26B | ||
AMGN | AMGEN INC | 13.01 | 152.81B | ||
GILD | GILEAD SCIENCES INC | 14.6 | 140.20B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 23.41 | 101.69B | ||
REGN | REGENERON PHARMACEUTICALS | 12.35 | 59.76B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.65B | ||
ARGX | ARGENX SE - ADR | 77.89 | 44.19B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.78 | 39.97B | ||
INSM | INSMED INC | N/A | 30.33B | ||
BNTX | BIONTECH SE-ADR | N/A | 24.14B | ||
NTRA | NATERA INC | N/A | 22.99B | ||
BIIB | BIOGEN INC | 8.85 | 20.76B |
Acurx Pharmaceuticals Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Staten Island, New York and currently employs 4 full-time employees. The company went IPO on 2021-06-25. Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The company develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug-resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme.
ACURX PHARMACEUTICALS INC
259 Liberty Avenue
Staten Island NEW YORK US
CEO: David P. Luci
Employees: 4
Phone: 19175331469
The current stock price of ACXP is 4.145 USD. The price decreased by -4.93% in the last trading session.
The exchange symbol of ACURX PHARMACEUTICALS INC is ACXP and it is listed on the Nasdaq exchange.
ACXP stock is listed on the Nasdaq exchange.
9 analysts have analysed ACXP and the average price target is 62.93 USD. This implies a price increase of 1418.31% is expected in the next year compared to the current price of 4.145. Check the ACURX PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ACURX PHARMACEUTICALS INC (ACXP) has a market capitalization of 6.55M USD. This makes ACXP a Nano Cap stock.
ACURX PHARMACEUTICALS INC (ACXP) currently has 4 employees.
ACURX PHARMACEUTICALS INC (ACXP) has a resistance level at 4.23. Check the full technical report for a detailed analysis of ACXP support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ACXP does not pay a dividend.
ACURX PHARMACEUTICALS INC (ACXP) will report earnings on 2025-11-11.
ACURX PHARMACEUTICALS INC (ACXP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.42).
ChartMill assigns a fundamental rating of 1 / 10 to ACXP. The financial health of ACXP is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months ACXP reported a non-GAAP Earnings per Share(EPS) of -4.42. The EPS decreased by -284.35% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -162.38% | ||
ROE | -280.37% | ||
Debt/Equity | 0 |
9 analysts have analysed ACXP and the average price target is 62.93 USD. This implies a price increase of 1418.31% is expected in the next year compared to the current price of 4.145.